Palmitoyl Tetrapeptide-7 vs Tirzepatide
Side-by-side comparison of key properties, dosing, and research.
Skin & Cosmetic
Palmitoyl Tetrapeptide-7GLP-1 / Weight Loss Agonists
Tirzepatide- Summary
- Palmitoyl Tetrapeptide-7 (Rigin) is a cosmetic peptide consisting of palmitic acid linked to the tetrapeptide sequence GQPR (Gly-Gln-Pro-Arg). It was designed to mimic the biological activity of the IgG immunoglobulin C-terminus, which downregulates the production of interleukin-6 (IL-6), a key driver of skin aging and inflammation.
- Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist that produces greater weight loss than semaglutide in head-to-head trials. SURMOUNT-1 trial showed average 21% body weight reduction at 72 weeks at the highest dose. Marketed as Mounjaro (diabetes) and Zepbound (obesity).
- Half-Life
- Topical penetration-dependent; effects last hours to days
- ~5 days
- Admin Route
- Topical
- SubQ
- Research
- —
- —
- Typical Dose
- 2-5 ppm concentration in formulation
- 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
- Frequency
- Twice daily
- Once weekly, subcutaneous
- Key Benefits
- Reduces IL-6 inflammatory cytokine in skin
- Prevents 'inflammaging' of the skin
- Inhibits MMP collagen-degrading enzymes
- Synergistic with Matrixyl for anti-aging
- Clinically tested for wrinkle and skin texture improvement
- Well-tolerated topically
- Average 21% body weight reduction at highest dose (SURMOUNT-1)
- Superior to semaglutide in head-to-head SURPASS trials
- Dual GIP/GLP-1 mechanism for enhanced metabolic control
- Significant reduction in HbA1c for type 2 diabetes
- Improved cardiovascular risk markers
- Reduces visceral fat preferentially
- FDA-approved for T2DM (Mounjaro) and obesity (Zepbound)
- Weekly dosing
- Side Effects
- Contact sensitization (rare)
- Well-tolerated at standard concentrations
- Nausea (most common during titration)
- Vomiting
- Diarrhea or constipation
- Abdominal pain
- +3 more
- Stacks With
- —
- —